Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3777, a hepatocyte growth factor mimetic for acute kidney injury, acute lung injury, acute respiratory distress syndrome, central nervous system injuries, and heart injuries. It also develops ANG-3070, a tyrosine kinase inhibitor and rho kinase 2 inhibitors for fibrotic diseases; and CYP11B2, an aldosterone synthase inhibitor for aldosterone-related fibrotic diseases. The company was incorporated in 1998 and is based in Uniondale, New York.
IPO Year: 2021
Exchange: NASDAQ
Website: angion.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/10/2021 | $15.00 → $8.00 | Outperform | Oppenheimer |
| 11/9/2021 | $100.00 → $50.00 | Buy | HC Wainwright & Co. |
| 10/27/2021 | $40.00 → $15.00 | Buy | Stifel |
Oppenheimer reiterated coverage of Angion Biomedica with a rating of Outperform and set a new price target of $8.00 from $15.00 previously
HC Wainwright & Co. reiterated coverage of Angion Biomedica with a rating of Buy and set a new price target of $50.00 from $100.00 previously
Stifel reiterated coverage of Angion Biomedica with a rating of Buy and set a new price target of $15.00 from $40.00 previously
HC Wainwright initiated coverage of Angion Biomedica with a rating of Buy and set a new price target of $100.00
Stifel Nicolaus initiated coverage of Angion Biomedica with a rating of Buy and set a new price target of $40.00
Cowen initiated coverage of Angion Biomedica with a rating of Outperform
Oppenheimer initiated coverage of Angion Biomedica with a rating of Outperform and set a new price target of $38.00
Oppenheimer initiated coverage of Angion Biomedica with a rating of Outperform and set a new price target of $38.00
Stifel initiated coverage of Angion Biomedica with a rating of Buy and set a new price target of $40.00
Cowen initiated coverage of Angion Biomedica with a rating of Outperform
4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)
SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)
SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)
SC 13G/A - Elicio Therapeutics, Inc. (0001601485) (Subject)
SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)
SC 13D - Elicio Therapeutics, Inc. (0001601485) (Subject)
SC 13D - Elicio Therapeutics, Inc. (0001601485) (Subject)
SC 13G/A - Angion Biomedica Corp. (0001601485) (Subject)
SC 13G/A - Angion Biomedica Corp. (0001601485) (Subject)
SC 13G/A - Angion Biomedica Corp. (0001601485) (Subject)
Merger to result in Nasdaq-listed company focused on developing immunotherapies based on Elicio's proprietary lymph node-targeting Amphiphile (AMP) technologyLead program of the combined company will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors, currently enrolling a Phase 1 trial for patients with pancreatic ductal adenocarcinoma and colorectal cancer Conference call to be held 8:00 am Eastern Time on Wednesday, January 18 BOSTON and UNIONDALE, N.Y., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, has entere
-- Angion to host a conference call today at 4:30 p.m. EST UNIONDALE, N.Y. and ST. GALLEN, Switzerland, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced results from the exploratory Phase 2 GUARD trial of Angion's ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary bypass at risk for developing acute kidney injury (CSA-AKI). The trial did not meet its primary endpoint of percentage increase in serum creatinine based upon the area under the curve (AUC). However, Angion and Vifor Pharma continue to review the data based on the signal demonstrated in the clinically relevant MAKE90 secondary endpoint. The GU
UNIONDALE, N.Y. and ST. GALLEN, Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced the Phase 3 trial of Angion's ANG-3777 did not demonstrate a statistically significant difference from placebo on the primary endpoint (eGFR at 12 months) in the population of deceased donor kidney transplant patients who were at risk for developing delayed graft function (DGF). ANG-3777 showed a modest but not statistically significant difference in eGFR of 53.3mL/min/1.73m2 versus 50.4mL/min/1.73m2 for placebo (2.9 mL/min/1.73m2, p=0.33). In addition, ANG-3777 demonstrated an inconsistent benefit on key secondary endpoints. Based upon these
4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)
8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)
8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)
8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)
D - Elicio Therapeutics, Inc. (0001601485) (Filer)
8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)
10-Q - Elicio Therapeutics, Inc. (0001601485) (Filer)
8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)
8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)
8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)
NEWTON, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Angion Biomedia Corp. (NASDAQ:ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10. Angion's common stock will begin trading on a split-adjusted basis when the market opens on June 2, 2023 under the new trading symbol "ELTX." As a result of the reverse stock split, the CUSIP number for Angion's common stock will now be 28657F103. The reverse stock split was previously approved by the stockholders of Ang
Merger to result in Nasdaq-listed company focused on developing immunotherapies based on Elicio's proprietary lymph node-targeting Amphiphile (AMP) technologyLead program of the combined company will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors, currently enrolling a Phase 1 trial for patients with pancreatic ductal adenocarcinoma and colorectal cancer Conference call to be held 8:00 am Eastern Time on Wednesday, January 18 BOSTON and UNIONDALE, N.Y., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, has entere
UNIONDALE, N.Y., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, announced that on December 15, 2022, it received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market notifying Angion that for the last 30 consecutive business days the bid price of Angion's common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq listing rule 5450(a)(1). The notification received has no immediate effect on the listin
UNIONDALE, N.Y. , Aug. 15, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today provided a corporate update and reported its financial results for the quarter ended June 30, 2022. On June 29, 2022, Angion announced discontinuation of JUNIPER, its Phase 2 dose-finding trial of ANG-3070 in patients with primary proteinuric kidney diseases, specifically focal segmental glomerulosclerosis (FSGS) and immunoglobulin A nephropathy (IgAN). This trial, which began enrolling patients in December 2021, was discontinued i
UNIONDALE, N.Y., July 25, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced it has commenced a process to explore and evaluate strategic options to enhance and preserve shareholder value. Angion's Board of Directors has approved engagement of Oppenheimer & Co., Inc. as the company's exclusive financial advisor to assist in this process. Potential strategic options to be explored or evaluated as part of this process may include, but are not limited to, merger, reverse merger, other business combination, sal
UNIONDALE, N.Y., June 29, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced the discontinuation of JUNIPER, its Phase 2 dose-finding trial of ANG-3070, an oral tyrosine kinase inhibitor (TKI), in patients with primary proteinuric kidney diseases, specifically focal segmental glomerulosclerosis (FSGS) and immunoglobulin A nephropathy (IgAN). This trial, which began enrolling patients in December 2021, is being discontinued in the interest of patient safety based upon a reassessment of the risk/benefit profile
-- Ended the quarter with $73M in cash and cash equivalents sufficient to fund operations well into 2023 UNIONDALE, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today provided a corporate update and reported its financial results for the quarter ended March 31, 2022. "In the first quarter of 2022, we made good progress on our strategic objectives for the year," said Dr. Jay R. Venkatesan, Angion's President and Chief Executive Officer. "Enrollment in JUNIPER, the Phase 2 dose-finding trial of our oral ty
-- The FDA has accepted an IND application supporting clinical development of ANG-3070 in IPF -- Phase 1b trial to be initiated to gather tolerability, safety, and pharmacokinetic data in IPF patients UNIONDALE, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced U.S. Food and Drug Administration's (FDA) acceptance of an Investigational New Drug (IND) application supporting the clinical development of ANG-3070 in idiopathic pulmonary fibrosis (IPF) and clearance to begin a Phase 1b study of ANG
UNIONDALE, N.Y., May 12, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced participation in an upcoming investment conference. Angion's President and CEO, Dr. Jay Venkatesan, will participate virtually in the H.C. Wainwright Global Investment Conference. Details are as follows: Event: H.C. Wainwright Global Investment ConferenceDate: Tuesday, May 24, 2022 Time: 7:00am Eastern US Time A webcast of the event will be accessible online by visiting the events and presentations page unde
UNIONDALE, N.Y., April 14, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced participation in an upcoming investment conference. Angion's President and CEO, Dr. Jay Venkatesan, will participate in the Shareholder Equity Conference, held virtually. The presentation will be a fireside chat format and investors will have the opportunity to ask management questions during the live presentation. Details are as follows: Shareholder Equity Conference (Virtual) Thursday, April 21, 2022 at 11:30 AM ET A webcast o